What We're Reading: Page 79
Industry reads hand-picked by our editors
Aug 17, 2023
-
The Wall Street Journal
A Big Health Insurer Is Ripping Up the Playbook on Drug Pricing
-
The New York Times
We Know Where New Weight Loss Drugs Came From, but Not Why They Work
-
Nature
Thousands of scientists are cutting back on Twitter, seeding angst and uncertainty
-
NBC News
Price gouging of cancer drugs in short supply hits some hospitals hard
Aug 16, 2023
Aug 15, 2023
-
The Wall Street Journal
He Developed a Drug to Treat Psoriasis. He Also Had the Disease Himself.
-
Reuters
What happens when a $2 million gene therapy is not enough
-
Axios
Venture capitalist’s cancer scare highlights debate over full-body scans
-
FirstWord Pharma
A decade after rejection, Delcath snags FDA approval of drug-device combo
Aug 14, 2023
-
AP news
Insurers won’t cover new Alzheimer’s treatment for some customers
-
Stat
FOP patients plead for FDA approval of drug despite muddled data
-
Fierce Pharma
Another round of layoffs hits BMS, with 100+ people impacted after earnings miss
-
The Wall Street Journal
Ozempic Settles the Obesity Debate: It’s Biology Over Willpower
Aug 11, 2023
Aug 10, 2023
Aug 09, 2023
-
Bloomberg
The Weight-Loss Drug Frenzy Is Outrunning the Company Behind It
-
Fierce Pharma
Mirati parts ways with CEO, lays out new Krazati-Keytruda trial plan in lung cancer
-
The Wall Street Journal
Drug Shortages Are a Boon to One Industry: Compounding Pharmacies
-
MIT Technology Review
After 25 years of hype, embryonic stem cells are still waiting for their moment
Previous
